Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

References

• AhlbergKEkmanTGaston-JohanssonFMockVAssessment and management of cancer-related fatigue in adultsLancet2003362938464065012944066
   PubMed Web of Science ®Google Scholar
• HarperPLittlewoodTAnaemia of cancer: impact on patient fatigue and long-term outcomeOncology200569Suppl 22716244504
   PubMed Web of Science ®Google Scholar
• WeisJCancer-related fatigue: prevalence, assessment and treatment strategiesExpert Rev Pharmacoecon Outcomes Res201111444144621831025
   PubMed Web of Science ®Google Scholar
• CamposMPHassanBJRiechelmannRDel GiglioACancer-related fatigue: a reviewRev Assoc Med Bras2011572211219 English, Portuguese21537710
   PubMed Web of Science ®Google Scholar
• IopAManfrediAMBonuraSFatigue in cancer patients receiving chemotherapy: an analysis of published studiesAnn Oncol200415571272015111337
   PubMed Web of Science ®Google Scholar
• MintonORichardsonASharpeMHotopfMStonePA systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigueJ Natl Cancer Inst2008100161155116618695134
   PubMedGoogle Scholar
• MintonORichardsonASharpeMHotopfMStonePDrug therapy for the management of cancer-related fatigueCochrane Database Syst Rev20107CD00670420614448
   PubMed Web of Science ®Google Scholar
• TonelliMHemmelgarnBReimanTBenefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCMAJ200918011E62E7119407261
   PubMed Web of Science ®Google Scholar
• BokemeyerCAaproMSCourdiAEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEur J Cancer200743225827017182241
   PubMed Web of Science ®Google Scholar
• AaproMSLinkHSeptember 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agentsOncologist200813Suppl 3333618458123
   PubMed Web of Science ®Google Scholar
• VansteenkisteJWautersIElliottSGlaspyJHedenusMChemotherapy-induced anemia: the story of darbepoetin alfaCurr Med Res Opin201329432533723323876
   PubMed Web of Science ®Google Scholar
• SchrijversDManagement of anemia in cancer patients: transfusionsOncologist201116Suppl 3121821930830
   PubMed Web of Science ®Google Scholar
• HauserKWalshDVisual analogue scales and assessment of quality of life in cancerJ Support Oncol20086627728218724538
   PubMedGoogle Scholar
• StonePRichardsonAReamESmithAGKerrDJKearneyNCancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue ForumAnn Oncol200011897197511038033
   PubMed Web of Science ®Google Scholar
• CellaDEtonDTLaiJSPetermanAHMerkelDECombining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scalesJ Pain Symptom Manage200224654756112551804
   PubMed Web of Science ®Google Scholar
• RevickiDACellaDHaysRDSloanJALenderkingWRAaronsonNKResponsiveness and minimal important differences for patient reported outcomesHealth Qual Life Outcomes200647017005038
   PubMed Web of Science ®Google Scholar
• CellaDQuality of life and clinical decisions in chemotherapy-induced anemiaOncology (Williston Park)2006208 Suppl 6252816925108
   PubMedGoogle Scholar
• Amgen Inc.Aranesp^® (darbepoetin alfa) Summary of Product CharacteristicsThousand OaksAmgen Inc.2012 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000332/WC500026149.pdfAccessed May 6, 2015
   Google Scholar
• PickardASNearyMPCellaDEstimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth Qual Life Outcomes200757018154669
   PubMed Web of Science ®Google Scholar
• RevickiDAStullDVernonMRaderMTomitaDViswanathanHNAssessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trialsQual Life Res201221231132121644007
   PubMed Web of Science ®Google Scholar
• BohliusJToniaTNueschEEffects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished dataBr J Cancer20141111334524743705
   PubMed Web of Science ®Google Scholar
• MartelliOGarassinoMSacchettaSDarbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT)Anticancer Res2008283B1767177118630457
   PubMed Web of Science ®Google Scholar
• LudwigHCrawfordJOsterborgAPooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemiaJ Clin Oncol200927172838284719380447
   PubMed Web of Science ®Google Scholar
• KerkhofsLBoschettiGLuginiAStanculeanuDLPalomoAGUse of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experienceFuture Oncol20128675175622443466
   PubMed Web of Science ®Google Scholar
• GómezASalgadoMValladares-AyerbesMEfficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapyClin Transl Oncol2010121284384821156416
   PubMed Web of Science ®Google Scholar
• VansteenkisteJPirkerRMassutiBDouble-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapyJ Natl Cancer Inst200294161211122012189224
   PubMed Web of Science ®Google Scholar
• PirkerRRamlauRASchuetteWSafety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposideJ Clin Oncol200826142342234918467726
   PubMed Web of Science ®Google Scholar
• HernandezEGanlyPCharuVRandomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemiaCurr Med Res Opin20092592109212019601709
   PubMed Web of Science ®Google Scholar
• KarlssonTEffects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agentsISRN Hematol2011201110839722111015
   PubMedGoogle Scholar
• Gafter-GviliARozen-ZviBVidalLIntravenous iron supplementation for the treatment of chemotherapy-induced anaemia – systematic review and meta-analysis of randomised controlled trialsActa Oncol2013521182922877242
   PubMed Web of Science ®Google Scholar
• PetrelliFBorgonovoKCabidduMLonatiVBarniSAddition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trialsJ Cancer Res Clin Oncol2012138217918721972052
   PubMed Web of Science ®Google Scholar